Actively Recruiting
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
Led by Myeloid Therapeutics · Updated on 2025-12-18
70
Participants Needed
9
Research Sites
204 weeks
Total Duration
On this page
Sponsors
M
Myeloid Therapeutics
Lead Sponsor
C
CREATE Medicines
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.
CONDITIONS
Official Title
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Diagnosis of advanced, recurrent, metastatic, or unresectable hepatocellular carcinoma (HCC)
- Measurable tumor lesion by RECIST 1.1 criteria
- ECOG performance status of 0 or 1
- Child-Pugh Class A liver function
- Adequate organ function
- For Module 1, participants with other GPC3-expressing tumors may be considered after medical review
- Only participants with HCC eligible for Module 2
You will not qualify if you...
- Active central nervous system metastases or carcinomatous meningitis
- Any acute illness including active infection
- History of liver transplantation or on transplant waiting list
- Untreated or incompletely treated varices with bleeding risk
- Uncontrolled pleural, pericardial effusion, or ascites
- History of symptomatic congestive heart failure
- Severe autoimmune or immune-mediated disease requiring steroids or immunosuppressants within the past year
- For Module 2: fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Significant cardiovascular disease
- Severe hypersensitivity to atezolizumab or bevacizumab
- History of idiopathic pulmonary fibrosis
- Prior hypertensive crisis or encephalopathy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
St Vincent's Hospital
Sydney, New South Wales, Australia, 2010
Actively Recruiting
2
Integrated Clinical Oncology Network (ICON) Pty Ltd
Woolloongabba, Queensland, Australia, 4102
Actively Recruiting
3
The Alfred Hospital
Melbourne, Victoria, Australia, 3004
Actively Recruiting
4
Linear Clinical Research
Murdoch, Western Australia, Australia, 6150
Actively Recruiting
5
Pusan National Univesity Hospital
Busan, South Korea
Actively Recruiting
6
Cha University Bundang Medical Center
Gyeonggi-do, South Korea
Actively Recruiting
7
Seoul National University Hospital
Seoul, South Korea
Actively Recruiting
8
National Taiwan University Hospital
Taipei, Taiwan
Actively Recruiting
9
Taipei Tzu Chi Hospital
Taipei, Taiwan
Actively Recruiting
Research Team
P
Project Manager
CONTACT
C
Clinical Department
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here